Email updates

Keep up to date with the latest news and content from BMC Complementary and Alternative Medicine and BioMed Central.

This article is part of the supplement: Scientific Abstracts Presented at the International Research Congress on Integrative Medicine and Health 2012

Open Access Poster presentation

P02.123. The anti-diabetic and cholesterol-lowering effects of common and cassia cinnamon (Cinnamomum verum and C. aromaticum): a randomized controlled trial

J Dugoua1*, D Perri2, D Seely3, J Ardilouze4, R Ridout5, K Bowers6, T Einarson1 and G Koren1

  • * Corresponding author: J Dugoua

Author Affiliations

1 University of Toronto, Toronto, Canada

2 McMaster University, Hamilton, Canada

3 Canadian College of Naturopathic Medicine, Toronto, Canada

4 Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada

5 Toronto Western Hospital, Toronto, Canada

6 University North Texas, Denton, USA

For all author emails, please log on.

BMC Complementary and Alternative Medicine 2012, 12(Suppl 1):P179  doi:10.1186/1472-6882-12-S1-P179


The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1472-6882/12/S1/P179


Published:12 June 2012

© 2012 Dugoua et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose

According to the World Health Organization (WHO), approximately 150 million people worldwide have type 2 diabetes. It is a growing health concern. Common and cassia cinnamon have been reported to have anti-diabetic and lipid-lowering effects. The objective was to determine if the combination of common and cassia cinnamon (Cinnamomum verum and C. aromaticum) reduces fasting blood glucose, insulin, glycosylated hemoglobin (HA1C), triglyceride, total cholesterol, HDL cholesterol and LDL cholesterol levels in people with type 2 diabetes.

Methods

Fifty (50) type 2 diabetic participants were randomized to receive either 140 mg of Cinnamonforce twice daily or placebo over 13 weeks. Physical and laboratory measurements were taken at baseline, 2 weeks, 4 weeks, 8 weeks and at the end of the trial, 13 weeks.

Results

There were no significant improvements in fasting glucose, insulin and lipid parameters between treatment and placebo groups. At endpoint, subjects in the treatment group were found to have a marginally non-significant higher fasting blood glucose level than subjects taking the placebo (p=0.085). There was a non-significant decrease in HA1c in the treatment group versus the placebo group (p=0.172). In secondary outcomes, significant differences in weight (p= 0.008), BMI (p= 0.001) and waist-to-hip ratio (p=0.020) were detected in the treatment versus placebo groups.

Conclusion

The combination of common and cassia cinnamon do not impact fasting glucose, insulin and lipid measurements. Through power calculations, there may be an effect on HA1c, however, the sample size in this study was not sufficient to detect a trend, if any. Although secondary outcomes in this study, common and cassia cinnamon should be further investigated for weight loss.